Revance Therapeutics's total assets for Q3 2024 were $461.56M, a decrease of -6.72% from the previous quarter. RVNC total liabilities were $624.59M for the fiscal quarter, a <0.01% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.